Apogee Therapeutics, Inc.

NASDAQ:APGE

Biotechnology

Healthcare
$135.07 +1.18%

+$1.05 today

Market cap
$8.36B
Beta
0.62
P/E (TTM)
-22.7
EPS (TTM)
-$3.94
52W Low $34.34High $95.32

Volume 0.00M

Average 0.97M

APGE Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Apogee Therapeutics, Inc.NASDAQ: APGE

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $67.3M rose 20.8% year over year, ahead of the +15.7% change in trailing-twelve-month research & development. Sequentially, it rose 10.7% from the prior quarter. Over 3 fiscal years it compounded at +97.7% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.8% holds above the trailing-twelve-month pace of +15.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$67.3M+10.7% QoQ
Last fiscal yearDec 2025
$214.71M+27.9% YoY
LTMJun 2026
$240.74M+15.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.8%——
1 year+27.9%——
3-year CAGR+97.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
214.71M USD
Year-over-year change
+27.9%
3-year CAGR
+97.7%

Research & Development vs competitors

How APGE compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.7% is the 5th highest of 10, against a peer median of +14.4%.
  • Over three fiscal years its annual growth of +97.7% compares with a peer median of +13.4%.
APGE Competitors
Research & Development for APGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥1.08B CNY+14.4%+13.4%194.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$770.95M USD+12.5%+2.0%115.2%
LEGNLegend Biotech CorporationLTM Sep 2026$378.58M USD-9.4%+7.3%27.9%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$371.08M USD+36.1%+41.7%—
APGEApogee Therapeutics, Inc.LTM Jun 2026$240.74M USD+15.7%+97.7%—
ZLABZai Lab LimitedLTM Jun 2026$236.92M USD+3.2%-8.3%52.7%
CNTACentessa Pharmaceuticals plcLTM Mar 2026$198.67M USD+23.4%+3.6%—
IRONDisc Medicine, Inc.LTM Sep 2026$183.14M USD+22.7%+72.2%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026$167.57M USD+47.7%+59.0%2717.6%
CELCCelcuity Inc.LTM Jun 2026$136.69M USD+2.4%+60.2%—
Peer median (excluding APGE) —+14.4%+13.4%115.2%

Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0001.42M
Gross Profit000(1.42M)
Gross Margin————
Research & Development27.79M68.42M167.87M214.71M
Selling, General & Admin2.94M24.58M49.01M70.88M
Operating Expenses30.73M93M216.87M284.18M
Depreciation & Amortization09.02M189K1.42M
EBITDA(39.79M)(74.97M)(181.94M)(254.15M)
EBITDA Margin————
Operating Income(30.73M)(93M)(216.87M)(285.6M)
Operating Margin————
Interest Income92K9.02M34.74M30.03M
Interest Expense9.15M000
Other Income / Expenses(9.06M)9.02M34.74M30.03M
Income Before Tax(39.79M)(83.99M)(182.13M)(255.57M)
Pre-Tax Margin————
Income Tax Expense0018K278K
Net Income(39.79M)(83.99M)(182.15M)(255.84M)
Net Margin————
EPS (Basic)(0.79)(1.66)(3.30)(4.22)
EPS (Diluted)(0.79)(1.66)(3.30)(4.22)
Weighted Avg Shares50.67M50.66M55.19M60.69M
Weighted Avg Shares (Diluted)50.67M50.66M55.19M60.69M

Apogee Therapeutics, Inc.

NASDAQ:APGE

Intrinsic Alpha fair value

Locked

Current Price

$135.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.